The DNA repair connection Tobacco smoke and other lung carcinogens cause tens of thousands of DNA lesions per cell per day. The efficiency with which cells repair this damage determines whether mutations accumulate and whether cancer develops. XRCC1 (X-ray repair cross-complementing protein 1) is a critical scaffold protein in the base excision repair (BER) pathway that corrects oxidative and alkylation damage.
Why SNPs matter Single nucleotide polymorphisms (SNPs) are common inherited variants where one DNA letter differs between individuals. The Arg399Gln variant (rs25487) in XRCC1 changes amino acid 399 from arginine to glutamine in the BRCT1 domain, a region that binds PARP1 and other DNA repair factors. This substitution reduces BER efficiency and has been studied as a risk modifier across multiple cancers.
Study design Smolarz and colleagues genotyped 118 surgically confirmed NSCLC patients and 60 healthy controls from a Polish population, comparing Arg399Gln genotype distributions and calculating odds ratios for cancer risk associated with each genotype and allele.
BER pathway overview Base excision repair removes damaged nucleotide bases one at a time. A glycosylase enzyme excises the damaged base, leaving an abasic site. APE1 then cleaves the DNA backbone, and DNA polymerase beta fills in the gap. XRCC1 acts as a molecular platform that recruits and coordinates these enzymes, particularly stabilizing DNA ligase III at the final ligation step.
The BRCT1 domain and PARP1 interaction At position 399, XRCC1 contains its BRCT1 domain which directly binds poly(ADP-ribose) (PAR) chains generated by PARP1 at damage sites. The glutamine substitution in Arg399Gln impairs this interaction, meaning the mutant protein is less efficiently recruited to DNA breaks and single-strand nicks.
Functional consequences Studies using lymphoblast cell lines from Gln/Gln carriers show measurably slower repair of alkylation and oxidative damage, higher levels of unrepaired DNA strand breaks after genotoxic challenge, and slightly elevated chromosomal instability. The magnitude of the repair deficit is modest, consistent with this being a susceptibility allele rather than a disease-causing mutation.
Dominant genotype in patients The Gln/Gln homozygous genotype was the most common genotype found in NSCLC patients, present in 58.78% of cases, compared to lower frequencies in the control group. This enrichment suggests that Gln/Gln carriers may face elevated cancer susceptibility in this population.
Protective effect of the Arg allele Logistic regression analysis showed that carrying at least one Arg allele was associated with a reduced odds ratio for NSCLC (OR = 0.48), meaning the ancestral arginine allele appeared protective relative to the glutamine-only genotype. This finding aligns with the functional data showing that the Arg protein supports better DNA repair.
Heterozygous carriers The Arg/Gln heterozygous genotype showed intermediate risk between the two homozygous groups, consistent with a co-dominant or additive model where each Gln allele incrementally reduces repair capacity. Statistical significance was achieved for the genotype distribution comparison between patients and controls (p < 0.05).
Adenocarcinoma versus squamous cell The study examined whether the Arg399Gln genotype distribution differed between adenocarcinoma and squamous cell carcinoma subtypes of NSCLC. Both major subtypes showed enrichment of the Gln allele, though the pattern was more pronounced in adenocarcinoma, suggesting that impaired BER may be more specifically implicated in adenocarcinoma pathogenesis.
Lymph node involvement Patients with lymph node-positive disease (N1-N2) showed a trend toward higher Gln allele frequency compared to node-negative patients, raising the possibility that impaired DNA repair may be associated not only with cancer initiation but also with more aggressive tumor biology promoting lymphatic spread.
Smoking interaction The authors explored whether the risk associated with Gln/Gln genotype was modified by smoking history. Current and former smokers carrying Gln/Gln showed the highest risk estimates, consistent with the hypothesis that reduced BER capacity is most damaging when carcinogen exposure from tobacco continuously generates the oxidative and alkylation damage that BER must repair.
Meta-analysis context Published meta-analyses across Asian, European, and American populations report conflicting associations between XRCC1 Arg399Gln and lung cancer risk. Some Asian studies show strong Gln risk effects while some European studies find null results, suggesting the effect may be modified by population-specific carcinogen exposures, linkage disequilibrium patterns, or co-occurring repair gene variants.
Polish population specifics The Arg399Gln allele frequencies in the Polish control population were consistent with other Central European data, with Gln allele frequency around 35-40%. However, the strong Gln/Gln enrichment in the Polish NSCLC cohort was more pronounced than some Western European studies, potentially reflecting regional differences in smoking patterns or environmental exposures.
Sample size limitation With 118 cases and 60 controls, this study is powered to detect only relatively large effect sizes. The moderate control group size increases the risk of false-positive genotype associations, and the results should be interpreted cautiously pending validation in larger independent cohorts.
Polygenic repair panels XRCC1 functions within a larger repair network alongside XRCC3, OGG1, APE1, and ERCC2. Studies examining multiple repair gene variants simultaneously consistently show stronger lung cancer risk prediction than any single SNP, suggesting that a BER/NER polygenic score may be more clinically informative than genotyping XRCC1 alone.
Pharmacogenomic relevance XRCC1 variants may influence response to platinum-based chemotherapy, which works by generating DNA crosslinks that require functional repair pathways for resistance. Patients with Gln/Gln genotype might theoretically have higher tumor sensitivity to platinum agents due to impaired repair capacity, though prospective clinical studies are needed to test this.
Toward clinical application For XRCC1 SNP testing to enter clinical practice, large multicenter prospective cohorts are needed to define risk thresholds, interaction effects with smoking and carcinogen exposure, and cost-effectiveness relative to established screening modalities. The current study represents an important regional data point but requires replication before guiding clinical decisions.